ADT
53
3
WEC
53
-2
LNC
39
3
CVX
47
3
PM
62
-2
PYPL
54
2
PSA
58
2
NWL
53
3
AN
58
4
WDC
47
4
BMY
60
2
MAS
58
2
WAT
55
2
NRG
49
-3
BA
54
5
XRX
44
3
FITB
63
3
URI
65
5
SWK
64
5
CTSH
56
2
ADT
53
3
WEC
53
-2
LNC
39
3
CVX
47
3
PM
62
-2
PYPL
54
2
PSA
58
2
NWL
53
3
AN
58
4
WDC
47
4
BMY
60
2
MAS
58
2
WAT
55
2
NRG
49
-3
BA
54
5
XRX
44
3
FITB
63
3
URI
65
5
SWK
64
5
CTSH
56
2
Financhill
Back

ProQR Therapeutics NV 10K Form

Buy
51

PRQR
ProQR Therapeutics NV

Last Price:
3.63
Seasonality Move:
8.38%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PRQR News And Ratings

See the #1 stock for the next 7 days that we like better than PRQR

PRQR Financial Statistics

Sales & Book Value

Annual Sales: $7.05M
Cash Flow: $-7.05M
Price / Cash Flow: 0
Annual Sales: $0.34
Price / Book: 13.74

Profitability

EPS (TTM): -0.31540
Net Income (TTM): $-26.04M
Gross Margin: $0
Return on Equity: -66.59%
Return on Assets: -19.08%

ProQR Therapeutics NV Earnings Forecast

Key ProQR Therapeutics NV Financial Ratios

  • The Selling, General & Administrative Expenses for PRQR have been equal to 249.25% of Gross Profit Margin.
  • The Research & Development expenses have been 386.06% of Revenue.
  • The Interest Expense is -4.28% of Operating Income.
  • The Net Earning history of PRQR is -431.67% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

ProQR Therapeutics NV Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: PRQR
CUSIP: N71542
Website: proqr.com

Debt

Debt-to-Equity Ratio: 0.18
Current Ratio: 2.33
Quick Ratio: 2.29

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

PRQR Technical Analysis vs Fundamental Analysis

Buy
51
ProQR Therapeutics NV (PRQR) is a Buy

Is ProQR Therapeutics NV a Buy or a Sell?